Published in Transfus Med Hemother on May 06, 2013
The Art of Compromise in Transfusion/Transplantation Medicine (and Some Parallels in Classical Literature). Transfus Med Hemother (2013) 0.75
Desensitization in HLA-incompatible kidney recipients and survival. N Engl J Med (2011) 6.72
Antibodies against MICA antigens and kidney-transplant rejection. N Engl J Med (2007) 5.31
Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection. N Engl J Med (2005) 4.84
Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence. Am J Transplant (2011) 4.06
Antibody-mediated microcirculation injury is the major cause of late kidney transplant failure. Am J Transplant (2009) 3.43
Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation. J Am Soc Nephrol (2010) 2.66
Consensus guidelines on the testing and clinical management issues associated with HLA and non-HLA antibodies in transplantation. Transplantation (2013) 2.55
Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant. Am J Transplant (2012) 2.46
Renal transplantation in patients with pre-transplant donor-specific antibodies and negative flow cytometry crossmatches. Am J Transplant (2007) 2.28
Donor-specific HLA antibodies in a cohort comparing everolimus with cyclosporine after kidney transplantation. Am J Transplant (2012) 1.78
No association of kidney graft loss with human leukocyte antigen antibodies detected exclusively by sensitive Luminex single-antigen testing: a Collaborative Transplant Study report. Transplantation (2011) 1.67
Pre-transplant assessment of donor-reactive, HLA-specific antibodies in renal transplantation: contraindication vs. risk. Am J Transplant (2003) 1.58
Baseline donor-specific antibody levels and outcomes in positive crossmatch kidney transplantation. Am J Transplant (2010) 1.56
Living donor kidney transplantation in crossmatch-positive patients enabled by peritransplant immunoadsorption and anti-CD20 therapy. Transpl Int (2012) 1.47
Clinical relevance of pretransplant donor-specific HLA antibodies detected by single-antigen flow-beads. Transplantation (2009) 1.47
"Natural" human leukocyte antigen antibodies found in nonalloimmunized healthy males. Transplantation (2008) 1.41
Clinical usefulness of a novel C1q assay to detect immunoglobulin G antibodies capable of fixing complement in sensitized pediatric heart transplant patients. J Heart Lung Transplant (2010) 1.31
Epitopes of human leukocyte antigen class I antibodies found in sera of normal healthy males and cord blood. Hum Immunol (2009) 1.29
Clinical relevance of pretransplant donor-directed antibodies detected by single antigen beads in highly sensitized renal transplant patients. Transplantation (2008) 1.13
Pretransplant donor-specific HLA class-I and -II antibodies are associated with an increased risk for kidney graft failure. Am J Transplant (2012) 1.13
Kidney graft failure and presensitization against HLA class I and class II antigens. Transplantation (2002) 1.04
Donor-specific antibody against denatured HLA-A1: clinically nonsignificant? Hum Immunol (2011) 1.01
Effect on kidney graft survival of reducing or discontinuing maintenance immunosuppression after the first year posttransplant. Transplantation (2008) 1.00
Enhanced kidney allocation to highly sensitized patients by the acceptable mismatch program. Transplantation (2009) 0.93
Presensitized kidney graft recipients with HLA class I and II antibodies are at increased risk for graft failure: a Collaborative Transplant Study report. Hum Immunol (2009) 0.93
HLA antibodies and the occurrence of early adverse events in the modern era of transplantation: a collaborative transplant study report. Transplantation (2009) 0.91
Heart transplantation with donor-specific antibodies directed toward denatured HLA-A*02:01: a case report. Hum Immunol (2011) 0.89
Persistently low transplantation rate of ABO blood type O and highly sensitised patients despite alternative transplantation programs. Transpl Int (2012) 0.88
An integrative approach for the transplantation of high-risk sensitized patients. Transplantation (2010) 0.88
Intact HLA not beta2m-free heavy chain-specific HLA class I antibodies are predictive of graft failure. Transplantation (2009) 0.86
Blood levels of donor-specific human leukocyte antigen antibodies after renal transplantation: resolution of rejection in the presence of circulating donor-specific antibody. Transplantation (2007) 0.86
It takes six to boogie: allocating cadaver kidneys in Eurotransplant. Transplantation (2004) 0.85
Challenging the golden standard in defining donor-specific antibodies: does the solid phase assay meet the expectations? Tissue Antigens (2011) 0.85
Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis. Nat Med (2011) 6.35
Antibodies against MICA antigens and kidney-transplant rejection. N Engl J Med (2007) 5.31
Inhibition of allogeneic T cell proliferation by indoleamine 2,3-dioxygenase-expressing dendritic cells: mediation of suppression by tryptophan metabolites. J Exp Med (2002) 3.75
Expanding the evidence base in transplantation: the complementary roles of randomized controlled trials and outcomes research. Transplantation (2008) 3.43
Consensus guidelines on the testing and clinical management issues associated with HLA and non-HLA antibodies in transplantation. Transplantation (2013) 2.55
C3 polymorphisms and allograft outcome in renal transplantation. N Engl J Med (2009) 2.29
Inhibitors of indoleamine-2,3-dioxygenase for cancer therapy: can we see the wood for the trees? Nat Rev Cancer (2009) 2.26
Critical evaluation of the amino acid triplet-epitope matching concept in cadaver kidney transplantation. Transplantation (2004) 2.13
Asymmetric dimethylarginine and progression of chronic kidney disease: the mild to moderate kidney disease study. J Am Soc Nephrol (2005) 2.00
Sustained low efficiency dialysis using a single-pass batch system in acute kidney injury - a randomized interventional trial: the REnal Replacement Therapy Study in Intensive Care Unit PatiEnts. Crit Care (2012) 1.90
IDO1 and IDO2 are expressed in human tumors: levo- but not dextro-1-methyl tryptophan inhibits tryptophan catabolism. Cancer Immunol Immunother (2008) 1.88
H-Y as a minor histocompatibility antigen in kidney transplantation: a retrospective cohort study. Lancet (2008) 1.85
Regulation of human auto- and alloreactive T cells by indoleamine 2,3-dioxygenase (IDO)-producing dendritic cells: too much ado about IDO? Blood (2004) 1.83
Serial peripheral blood perforin and granzyme B gene expression measurements for prediction of acute rejection in kidney graft recipients. Am J Transplant (2003) 1.76
Renal insulin resistance syndrome, adiponectin and cardiovascular events in patients with kidney disease: the mild and moderate kidney disease study. J Am Soc Nephrol (2005) 1.74
The effect of donor gender on graft survival. J Am Soc Nephrol (2002) 1.72
No association of kidney graft loss with human leukocyte antigen antibodies detected exclusively by sensitive Luminex single-antigen testing: a Collaborative Transplant Study report. Transplantation (2011) 1.67
Salinomycin induces apoptosis and overcomes apoptosis resistance in human cancer cells. Biochem Biophys Res Commun (2009) 1.65
Salinomycin overcomes ABC transporter-mediated multidrug and apoptosis resistance in human leukemia stem cell-like KG-1a cells. Biochem Biophys Res Commun (2010) 1.62
Dysregulated cytokine responses during cytomegalovirus infection in renal transplant recipients. Transplantation (2008) 1.55
Living kidney donor follow-up: state-of-the-art and future directions, conference summary and recommendations. Am J Transplant (2011) 1.51
Malignancy in renal transplantation. J Am Soc Nephrol (2004) 1.50
Levo- but not dextro-1-methyl tryptophan abrogates the IDO activity of human dendritic cells. Blood (2007) 1.48
Living donor kidney transplantation in crossmatch-positive patients enabled by peritransplant immunoadsorption and anti-CD20 therapy. Transpl Int (2012) 1.47
Urinary proinflammatory cytokine response in renal transplant recipients with polyomavirus BK viruria. Transplantation (2009) 1.47
Studying the immunosuppressive role of indoleamine 2,3-dioxygenase: tryptophan metabolites suppress rat allogeneic T-cell responses in vitro and in vivo. Transpl Int (2005) 1.43
Ex vivo perfusion with mitomycin C containing solution prolongs heart graft survival in rats. Transplantation (2006) 1.41
Kidney graft survival in Europe and the United States: strikingly different long-term outcomes. Transplantation (2013) 1.36
A cell line model for the differentiation of human dendritic cells. Biochem Biophys Res Commun (2005) 1.28
Defective DNA mismatch repair in acute myeloid leukemia/myelodysplastic syndrome after organ transplantation. Blood (2004) 1.26
Increased expression and altered subunit composition of proteasomes induced by continuous proteasome inhibition establish apoptosis resistance and hyperproliferation of Burkitt lymphoma cells. J Cell Biochem (2008) 1.20
Proteasome inhibition suppresses essential immune functions of human CD4+ T cells. Immunology (2008) 1.14
The Risk of Transplant Failure With HLA Mismatch in First Adult Kidney Allografts From Deceased Donors. Transplantation (2016) 1.13
Cytokine expression during early and late phase of acute Puumala hantavirus infection. BMC Immunol (2011) 1.09
Molecular mechanisms of the antiangiogenic and antitumor effects of mycophenolic acid. Mol Cancer Ther (2008) 1.09
The immunoregulatory role of IDO-producing human dendritic cells revisited. Trends Immunol (2006) 1.07
Damage to the peritoneal membrane by glucose degradation products is mediated by the receptor for advanced glycation end-products. J Am Soc Nephrol (2005) 1.07
Three-year outcomes following 1420 ABO-incompatible living-donor kidney transplants performed after ABO antibody reduction: results from 101 centers. Transplantation (2015) 1.05
No improvement of patient or graft survival in transplant recipients treated with angiotensin-converting enzyme inhibitors or angiotensin II type 1 receptor blockers: a collaborative transplant study report. J Am Soc Nephrol (2006) 1.05
Kidney graft failure and presensitization against HLA class I and class II antigens. Transplantation (2002) 1.04
Retinoid receptor-specific agonists alleviate experimental glomerulonephritis. Am J Physiol Renal Physiol (2002) 1.04
Metabolic control improves long-term renal allograft and patient survival in type 1 diabetes. J Am Soc Nephrol (2008) 1.02
Active-specific immunotherapy of human cancers with the heat shock protein Gp96-revisited. Int J Cancer (2012) 1.00
Effect on kidney graft survival of reducing or discontinuing maintenance immunosuppression after the first year posttransplant. Transplantation (2008) 1.00
Inosine monophosphate dehydrogenase polymorphisms and renal allograft outcome. Transplantation (2012) 0.99
Donor ABCB1 variant associates with increased risk for kidney allograft failure. J Am Soc Nephrol (2012) 0.98
Pre- and posttransplantation allosensitization in heart allograft recipients: major impact of de novo alloantibody production on allograft survival. Hum Immunol (2010) 0.97
Successful treatment of chronic antibody-mediated rejection with IVIG and rituximab in pediatric renal transplant recipients. Transplantation (2008) 0.97
Salinomycin in cancer: A new mission for an old agent. Mol Med Rep (2011) 0.97
Color doppler ultrasonography in the diagnostic evaluation of renal allografts. Nephron Clin Pract (2006) 0.96
Kidney transplantation across HLA and ABO antibody barriers. Curr Opin Organ Transplant (2013) 0.96
Late referral--a major cause of poor outcome in the very elderly dialysis patient. Nephrol Dial Transplant (2006) 0.95
CD4+CD25+Foxp3+IFN-γ+ human induced T regulatory cells are induced by interferon-γ and suppress alloresponses nonspecifically. Hum Immunol (2011) 0.93
Associations of dichlorodiphenyltrichloroethane (DDT) 4.4 and dichlorodiphenyldichloroethylene (DDE) 4.4 blood levels with plasma IL-4. Arch Environ Health (2003) 0.93
Presensitized kidney graft recipients with HLA class I and II antibodies are at increased risk for graft failure: a Collaborative Transplant Study report. Hum Immunol (2009) 0.93
IVIG and rituximab for treatment of chronic antibody-mediated rejection: a prospective study in paediatric renal transplantation with a 2-year follow-up. Transpl Int (2012) 0.93
Antithymocyte globulins suppress dendritic cell function by multiple mechanisms. Transplantation (2007) 0.92
HLA antibodies and the occurrence of early adverse events in the modern era of transplantation: a collaborative transplant study report. Transplantation (2009) 0.91
Observational support for an immunoregulatory role of CD3+CD4+CD25+IFN-gamma+ blood lymphocytes in kidney transplant recipients with good long-term graft outcome. Transpl Int (2008) 0.90
Aquaporin-1 channel function is positively regulated by protein kinase C. J Biol Chem (2007) 0.89
ABO-incompatible kidney transplantation enabled by non-antigen-specific immunoadsorption. Transplantation (2012) 0.89
HLA matching and kidney transplantation: beyond graft survival. Clin Transpl (2013) 0.88
An integrative approach for the transplantation of high-risk sensitized patients. Transplantation (2010) 0.88
A new epitope-based HLA-DPB matching approach for cadaver kidney retransplants. Transplantation (2003) 0.88
Current role of human leukocyte antigen matching in kidney transplantation. Curr Opin Organ Transplant (2013) 0.88
Proteasomal chymotrypsin-like peptidase activity is required for essential functions of human monocyte-derived dendritic cells. Immunology (2006) 0.87
Real-time contrast-enhanced sonography in renal transplant recipients. Clin Transplant (2006) 0.86
Interferon-gamma producing regulatory T cells as a diagnostic and therapeutic tool in organ transplantation. Int Rev Immunol (2013) 0.86
Strong inflammatory cytokine response in male and strong anti-inflammatory response in female kidney transplant recipients with urinary tract infection. Transpl Int (2005) 0.86
Sodium citrate anticoagulation during sustained low efficiency dialysis (SLED) in patients with acute renal failure and severely impaired liver function. Nephrol Dial Transplant (2007) 0.86
Polymorphisms of the tumor necrosis factor-alpha gene promoter predict for outcome after thalidomide therapy in relapsed and refractory multiple myeloma. Blood (2002) 0.86
Evaluation of T-cell receptor repertoires in patients with long-term renal allograft survival. Am J Transplant (2005) 0.86
Salt--a potential 'uremic toxin'? Blood Purif (2006) 0.86
CD4+ CD25+ Foxp3+ IFNγ+ CD178+ human induced Treg (iTreg) contribute to suppression of alloresponses by apoptosis of responder cells. Hum Immunol (2012) 0.86
The long-term consequences of living-related or unrelated kidney donation. Nephrol Dial Transplant (2004) 0.86
Bleeding complications in pediatric ABO-incompatible kidney transplantation. Pediatr Nephrol (2012) 0.86
RAGE expression in the human peritoneal membrane. Nephrol Dial Transplant (2008) 0.85
Sequential analysis by immunoprecipitation-MALDI-TOF: a novel method for detection and identification of alloantibody specificities. Hum Immunol (2010) 0.85
Risks of allogeneic hand transplantation. Microsurgery (2004) 0.84
Generation of tolerogenic dendritic cells by treatment with mitomycin C: inhibition of allogeneic T-cell response is mediated by downregulation of ICAM-1, CD80, and CD86. Transplantation (2004) 0.84
Apoptosis-mediated selective killing of malignant cells by cardiac steroids: maintenance of cytotoxicity and loss of cardiac activity of chemically modified derivatives. Int Immunopharmacol (2003) 0.84
HMG-CoA reductase inhibitor simvastatin overcomes bortezomib-induced apoptosis resistance by disrupting a geranylgeranyl pyrophosphate-dependent survival pathway. Biochem Biophys Res Commun (2008) 0.84
Release of soluble CD30 after allogeneic stimulation is mediated by memory T cells and regulated by IFN-γ and IL-2. Transplantation (2013) 0.84
CD4(+)CD25(+)Foxp3(+)IFNγ(+) Treg are immunosuppressive in vitro and increase with intensity of the alloresponse in pretransplant MLC. Transpl Immunol (2012) 0.83
Increased pretransplantation plasma kynurenine levels do not protect from but predict acute kidney allograft rejection. Hum Immunol (2010) 0.83
The effect of ATG on cytokine and cytotoxic T-lymphocyte gene expression in renal allograft recipients during the early post-transplant period. Clin Transplant (2003) 0.83
A simplified technique for heart transplantation in rats: abdominal vessel branch-sparing and modified venotomy. Microsurgery (2006) 0.83
Immunosuppressive anti-immunoglobulin autoantibodies: specificity, gene structure and function in health and disease. Cell Mol Biol (Noisy-le-grand) (2002) 0.83
Decreasing plasma soluble IL-1 receptor antagonist and increasing monocyte activation early post-transplant may be involved in pathogenesis of delayed graft function in renal transplant recipients. Clin Transplant (2009) 0.83
Impact of HLA matching and HLA antibodies in organ transplantation: a collaborative transplant study view. Methods Mol Biol (2012) 0.83
Short communication: decreasing soluble CD30 and increasing IFN-gamma plasma levels are indicators of effective highly active antiretroviral therapy. AIDS Res Hum Retroviruses (2007) 0.82
Suppressive dendritic cells as a tool for controlling allograft rejection in organ transplantation: promises and difficulties. Hum Immunol (2008) 0.82
Posttransplant sCD30 as a biomarker to predict kidney graft outcome. Clin Chim Acta (2011) 0.82
Association of Kidney Graft Loss With De Novo Produced Donor-Specific and Non-Donor-Specific HLA Antibodies Detected by Single Antigen Testing. Transplantation (2015) 0.82
Impact of maintenance immunosuppressive regimens--balance between graft protective suppression of immune functions and a near physiological immune response. Transpl Int (2011) 0.82
Outcomes Following ABO-Incompatible Kidney Transplantation Performed After Desensitization by Nonantigen-Specific Immunoadsorption. Transplantation (2015) 0.82
A fast and simple method for detecting and quantifying donor-derived cell-free DNA in sera of solid organ transplant recipients as a biomarker for graft function. Clin Chem Lab Med (2016) 0.81
Can intravenous immunoglobulin and simvastatin solve the problem of sensitization in renal transplant candidates? Int Urol Nephrol (2007) 0.81